TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Suvorexant in Insomnia Co-morbid With Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* meet Diagnostic and Statistical Manual 5th ed criteria for insomnia~* meet American College of Rheumatology criteria for fibromyalgia~* otherwise good psychiatric and stable physical health~Exclusion Criteria:~* other primary sleep disorders~* pain symptoms unrelated to fibromyalgia~* current pregnancy or breast-feeding

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- suvorexant (Type: EXPERIMENTAL): 9 nights of 20 mg suvorexant
- placebo (Type: PLACEBO_COMPARATOR): 9 nights placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Baerveldt Plate Area Comparison (BPAC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18~* Intra-Ocular Pressure (IOP) \> 18 mm Hg and \< 40 mm Hg on medical therapy~* Previous ocular surgery limited to (cataract, corneal transplant, trabeculectomy, vitrectomy)~* Consent signed~Exclusion Criteria:~* Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits~* Pregnant or nursing~* Neuro-Linguistic Programming (NLP) vision~* Iris neovascularization or proliferative retinopathy~* Epithelial or fibrous downgrowth~* Chronic or recurrent uveitis~* Steroid-induced glaucoma~* Severe posterior blepharitis~* Previous cyclodestructive procedure~* Conjunctival scarring from prior ocular trauma or cicatrizing disease (e.g. Stevens Johnson syndrome, ocular pemphigoid) precluding Baerveldt implantation.~* Functionally significant cataract~* Need for Baerveldt implant combined with other ocular procedures (ie cataract surgery,penetrating keratoplasty, or retinal surgery) or anticipated need for additional ocular surgery~* Prior glaucoma drainage device (tube) implant~* Prior retinal surgery with remaining silicone oil~* Prior scleral buckling procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A - Baerveldt 250 mm2 (Type: EXPERIMENTAL): Patients receiving Baerveldt 250 mm2
- Arm B - Baerveldt 350 mm2 (Type: EXPERIMENTAL): Patients receiving Baerveldt 350 mm2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Microneedles for Diagnosis of LTBI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Sex : Male and Female~2. Age : 20-60 years~3. TB contacts or those at risk of TB e.g. health-care workers~4. HIV-negative healthy individuals~Exclusion Criteria:~1. Presence of an acute infection, as determined by investigators~2. Receiving immunosuppression drugs e.g. steroids~3. Having autoimmune diseases e.g. SLE (Systemic Lupus Erythematous)~4. Being pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- volunteers (Type: OTHER): two different types of diagnostic tools (TST vs microneedle) will be used to screen for latent TB infection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Testosterone & Tamoxifen Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male~2. A history of proven ER+ (\>10% of cells), AR+ (\>10% of cells), and HER2- metastatic BC~3. Tumor progression after at least one line of conventional endocrine therapy (tamoxifen, AI, fulvestrant, CDK4/6, ±LHRH analogue).~4. Age ≥ 18 years~5. Adequate hematological, renal and liver function as follows:~   * Absolute neutrophil count \> 1.5 x 109/L~  * Platelet count \>100 x 109/L~  * White blood cell count \>3 x 109/L~  * AST and ALT \<2.5 or \<5.0 in case of liver metastases x upper limit of normal (ULN)~  * Creatinine clearance \>50mL/min~  * Prothrombin time, partial thromboplastin time and INR \<1.5 x ULN~6. Written informed consent~Exclusion Criteria:~1. History of prostate, testicular or liver cancer~2. Patients already using testosterone supplements~3. Patients using medication with anti-androgenic effects (e.g. spironolactone)~4. Elevated PSA (\>4μg/L) or severe urinary tract problems (as defined with a Prostate Symptom Score \>19). Patients with known BRCA mutation and PSA \>3 μg/L will be referred to the urologist for prostate cancer screening, and can participate if they have no signs of prostate cancer.~5. Hematocrit \>50%~6. Patients with uncontrolled hypertension, diabetes mellitus or other significant cardiovascular morbidity.~7. Patients with recent history of coronary artery disease or trombo-embolic events within 6 months prior to screening~8. Severe concurrent disease, infection, co morbid condition that, in the judgment of the investigator would make the patient inappropriate for enrollment~9. Visceral crisis and/or rapid progression necessitating chemotherapy~10. Previous allergic reaction to androgen agonists~11. Contra-indication for PET imaging~12. Tamoxifen or fulvestrant treatment \<5 weeks prior to FES-PET.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trabectome Versus Trabeculectomy With Mitomycin C in Patients With Open Angle Glaucoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 40-85 years~2. Open angle glaucoma (including pseudo exfoliative glaucoma)~3. Open angles (≥ Shaffer grade II)~4. Inadequately controlled IOP requiring surgical intervention~5. Visually significant cataract~6. Willing to complete quality of life questionnaires~7. Capable of informed consent and available for at least 1 year follow-up~Exclusion Criteria:~1. Any form of angle closure glaucoma~2. Secondary open angle glaucomas~3. Absence of clear angle landmarks on gonioscopy~4. Other ocular disease that may affect assessments of visual acuity, visual field, or accurate tonometry~5. Previous angle surgery or filtering procedure~6. Steroid use within the preceding 3 months~7. Presence of significant co-morbidities

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Trabectome-IOL (Type: ACTIVE_COMPARATOR): Combined Trabectome and cataract extraction with intraocular lens insertion
- Trab-IOL (Type: ACTIVE_COMPARATOR): Combined Trabeculetomy with Mitomycin C and cataract extraction with intraocular lens insertion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PANenteric Crohn's Capsule Versus Ileo-Colonoscopy and Scan Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-75~* Established diagnosis of Crohn's disease~* Patients who have been referred for IC and MRE for CD assessment as deemed appropriate by referring clinician as part of standard care~Exclusion Criteria:~* Indeterminate colitis or ulcerative colitis~* Stricturing disease - history consistent with obstruction e.g. nausea, vomiting, abdominal pain, bloating after meals or stricture seen on previous imaging~* Enteric fistulating disease based on clinical examination or previous imaging (perianal fistulae alone is allowed in the absence of anal strictures)~* Previous small bowel or colonic resection within 12 months~* Known or suspected bowel dysmotility~* Previous pelvic radiotherapy~* Insulin-treated diabetes mellitus~* Pregnancy~* Recent non-steroidal agent use within 4 weeks of study entry (excluding aspirin \<150mg per day)~* Contraindications to MRE, IC or capsule endoscopy~* Contraindications to taking bowel preparation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Crohn's capsule (Type: OTHER): Single-arm non-randomised study, all participants will undergo MRE, ileo-colonoscopy and Crohn's capsule.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* New York Heart Association (NYHA) Functional class Ⅲ or Ⅳ~* Left Ventricular Ejection Fraction (LVEF) \<35%~* Nonischemic cardiomyopathy~* Preserved renal function: Cr ≤2.5 mg/dL in males; Cr ≤2.0mg/dL in females~Exclusion Criteria:~* Hyperkalemia (≥5.0 mEg/L)~* Left ventricular systolic dysfunction with pericardial diseases, congenital heart diseases, pulmonary heart diseases, heart valvular diseases, acute coronary syndrome and short life expectancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vascular Implications of a Naturally Occurring Asthma Exacerbation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* between the ages of 18 and 55 years old~* waist circumference less than 88 cm for women and 102 cm for men.~* Asthma participants will be recruited from the University of Alberta Emergency Department with asthma exacerbation as their primary reason for visit.~* healthy controls will be recruited from the general population according to the same criteria, but with no history of asthma.~Exclusion Criteria:~* known heart failure or unstable cardiac disease,~* lung diseases other than asthma,~* known chronic inflammatory condition other than asthma~* known metabolic disease~* current infections,~* smoking history \> 10 pack years,~* or waist circumference \>88 cm for women and \>102 cm for men

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Control (Type: None): Healthy controls will be recruited from the general population and will be matched based on age, sex, and BMI. They will be assess at two time points, 48 hours apart. At each testing day, a blood sample will be taken, and endothelial function will be assessed using brachial artery flow mediated dilation. Arterial stiffness will be assessed using carotid-radial pulse wave velocity.
- Asthma (Type: None): Individuals experiencing an asthma exacerbation will be recruited from the University of Alberta Hospital Emergency Department. Once discharged, a blood sample will be taken, and endothelial function will be assessed using brachial artery flow mediated dilation. Arterial stiffness will be assessed using carotid-radial pulse wave velocity. Participants will complete the same assessments at a follow up date 48 hours and 14 days post-discharge, with the addition of a full pulmonary function test, physical activity assessment via a Fitbit, and the completion of two questionnaires: Asthma Control Questionnaire, and Asthma Quality of Life Questionnaire.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Alzheimer Disease : Rehabilitation's Intervention at Home

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Patient's inclusion criteria:~* Aged 65 and over~* AD or mixed dementia (DSM IV TR criteria), documented by a neuropsychological assessment and a brain imaging~* Living at home~* Having a caregiver (more than 2 visits per week)~* Agreement for the study~Caregiver's inclusion criteria :~* More than 2 patient's visits per week~* Agreement for the study~Patient's exclusion criteria:~* Life expectancy less than 1 year~* Guardianship~* Already having a rehabilitation program's therapy~* Participation in a pharmacological study~Caregiver's exclusion criteria:~- Medical condition requiring regular care

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Home rehabilitation therapy (Type: EXPERIMENTAL): 12 weekly sessions of Home rehabilitation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Contrast Injection Force on the Accuracy of Vessel Measurements in Cerebral Angiography

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving care at WFBMC that will be undergoing a standard of care cerebral angiogram who are anticipated to have a minimum of 2 images for an individual view required for the necessary data collection~Exclusion Criteria:~* Patients who are anticipated to have less than 2 images for each standard view collected from their cerebral angiogram.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care Cerebral Angiogram Group (Type: None): Participants undergoing a standard of care cerebral angiogram.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Angioplasty in the Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are willing to comply with the protocol requirements and can be contacted by telephone~* Patients 18-60 years of age~* Patients with clinically definite multiple sclerosis by Polman criteria~* Patients with a history of MS as defined above with an EDSS between 3-6.~* Patients with a significant stenosis of the internal jugular or azygos vein on the basis of magnetic resonance venography or Doppler ultrasound.~Exclusion Criteria:~* Patients with renal insufficiency based on an estimated GFR \<45~* Patients with a known severe allergy to iodine or gadolinium-based contrast agents which cannot be adequately pre-medicated~* Patients with a known allergy to nickel~* Patients who pregnant~* Patients with a contraindication to anticoagulation or anti-platelet medication~* Patients with a contraindication to drugs used for conscious sedation during interventional procedures, including Versed and Fentanyl~* Patients with a history of deep venous thrombosis of the lower extremities~* Patients with occlusion of the right and left common femoral veins~* Patients who have had any changes in their disease modifying drug regimen for MS during the 6 months prior to enrollment in this trial. This would include the addition of any new medications, a change in the dosage of any medications, or the removal of any medications from a patient's drug regimen~* Patients with a life expectancy \<18 months~* Patients who are currently enrolled or who plan to enroll in other investigations that conflict with follow-up testing or confounds data in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Treatment of CCSVI with Angioplasty (Type: EXPERIMENTAL): At the time of venography, these patients will have had a significant lesion (blockage) in the internal jugular and/or the azygos vein that will be treated with angioplasty.
- Observation of CCSVI (Type: SHAM_COMPARATOR): At the time of venography, these patients will have had a significant lesion (blockage) in the internal jugular and/or the azygos vein that will not be treated with angioplasty. These patients will be observed after treatment and compared to those patients who received treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-Contrast Magnetic Resonance Angiography Assessment of Patients Referred for Transcatheter Aortic Valve Implantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults with severe aortic stenosis referred for possible transcatheter aortic valve implantation with clinically indicated computed tomography imaging~Exclusion Criteria:~* Inability or unwillingness to consent~* Inability to complete magnetic resonance imaging (MRI) study~* Contraindication to MRI~* Participation in another research study~* Non-diagnostic computed tomography scan

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Removal Versus Retention of Cerclage in Preterm Premature Rupture of Membranes (PPROM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A previously placed prophylactic cerclage defined as any cerclage done \< 23 6/7 weeks including those done for previous history of cervical incompetence, asymptomatic cervical shortening (regardless of effacement) and asymptomatic cervical dilation \< 3 cm~2. Spontaneous rupture of membranes 22-32 weeks~3. Singleton or twin gestation~4. Shirodkar or McDonald cerclage in place \> 1 week~Exclusion Criteria:~1. Active labor (\> 8 uterine contractions \[UCs\] per hour)~2. Chorioamnionitis as defined by temperature \> 38 plus fetal tachycardia or uterine tenderness~3. Placenta previa or undiagnosed vaginal bleeding~4. Nonreassuring fetal status by nonstress test (NST) or biophysical profile (BPP)~5. Mature pulmonary studies~6. Positive gram stain, culture, white blood cells (WBC) \> 30, or glucose \< 14 on amniocentesis~7. Major fetal anomaly~8. Presentation \> 48 hours after rupture of membranes~9. abdominal cerclage~10. Cerclage done for symptomatic cervical dilation (cervix dilated \> 3 cm)~11. Post amniocentesis membrane rupture (rupture which occurs within one week of amniocentesis)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 Retention of Cerclage (Type: ACTIVE_COMPARATOR): Group one = Subject whose Cerclage is retained after randomization.
- 2 - Removal of Cerclage (Type: ACTIVE_COMPARATOR): Group 2 = Subjects who will have cerclage removed after randomization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dual Chamber Versus Single Chamber Cardiac Pacing in People 80 Years of Age and Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 80 years of age and older~* Symptomatic bradycardia~Exclusion Criteria:~* Permanent atrial fibrillation~* Previous pacemaker implant~* Life expectancy less than 1 year~* Geographic isolation~* Unable to give informed consent

- Gender: ALL
- Minimum Age: 80 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
- 2 (Type: OTHER): Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues